Michael Raab - Ardelyx CEO and President and Director
| ARDX Stock | USD 5.49 0.12 2.23% |
CEO
Mr. Michael G. Raab is President, Chief Executive Officer, Director of the Company. From 2002 to 2009, Mr. Raab was a partner at NEA, where he focused on investments in the biotechnology and pharmaceutical sectors. Prior to joining NEA, Mr. Raab spent 15 years in commercial and operating leadership roles in the biotech and pharmaceutical industries. He was Senior Vice President, Therapeutics and General Manager of the Renal Division at Genzyme Corporationrationration, or Genzyme, a biotechnology company. Mr. Raab also spent two years with Genzymes diagnostic products and services division. Before Genzyme, Mr. Raab held business development and sales and marketing positions at Repligen Corporationrationration, a life sciences company, and BristolMyers Corporationrationration. Mr. Raab is currently a director of Amicus Therapeutics, Inc. . Mr. Raab currently serves as a member of the board of directors of the California Life Sciences Association, a nonprofit trade association serving the life science industry in California, and as a member of the Emerging Companies Section Governing Board of the Biotechnology Innovation Organization since 2009.
| Age | 60 |
| Tenure | 16 years |
| Address | 400 Fifth Avenue, Waltham, MA, United States, 02451 |
| Phone | 510 745 1700 |
| Web | https://www.ardelyx.com |
Latest Insider Transactions
| 2025-03-07 | Disposed of 41668 shares @ 5.36 | View | |
| 2025-02-20 | Disposed of 22964 shares @ 5.62 | View | |
| 2025-01-31 | Disposed of 41666 shares @ 5.36 | View | |
| 2025-01-07 | Disposed of 41666 shares @ 5.31 | View | |
| 2024-12-10 | Disposed of 25000 shares @ 5.26 | View | |
| 2024-11-25 | Disposed of 25000 shares @ 5.38 | View | |
| 2024-11-11 | Disposed of 2743 shares @ 4.9 | View | |
| 2024-10-28 | Disposed of 25000 shares @ 5.91 | View | |
| 2024-10-11 | Disposed of 7500 shares @ 6.01 | View |
Michael Raab Latest Insider Activity
Tracking and analyzing the buying and selling activities of Michael Raab against Ardelyx stock is an integral part of due diligence when investing in Ardelyx. Michael Raab insider activity provides valuable insight into whether Ardelyx is net buyers or sellers over its current business cycle. Note, Ardelyx insiders must abide by specific rules, including filing SEC forms every time they buy or sell Ardelyx'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Michael Raab over a month ago Disposition of 20833 shares by Michael Raab of Ardelyx at 0.99 subject to Rule 16b-3 | ||
Michael Raab over three months ago Disposition of 25000 shares by Michael Raab of Ardelyx at 5.3793 subject to Rule 16b-3 | ||
Michael Raab over six months ago Disposition of 1229 shares by Michael Raab of Ardelyx at 5.71 subject to Rule 16b-3 | ||
Michael Raab over six months ago Disposition of 35000 shares by Michael Raab of Ardelyx at 0.99 subject to Rule 16b-3 |
Ardelyx Management Efficiency
The company has return on total asset (ROA) of (0.0476) % which means that it has lost $0.0476 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2301) %, meaning that it created substantial loss on money invested by shareholders. Ardelyx's management efficiency ratios could be used to measure how well Ardelyx manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.09 in 2025. Return On Capital Employed is likely to drop to -0.08 in 2025. At this time, Ardelyx's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 83.3 M in 2025, whereas Total Current Assets are likely to drop slightly above 183.9 M in 2025.Similar Executives
| Found 9 records | CEO Age | ||
| Lonnel Coats | Lexicon Pharmaceuticals | 59 | |
| Denise ScotsKnight | Mereo BioPharma Group | 66 | |
| Daniel Paterson | Verastem | 64 | |
| Michael Exton | Lexicon Pharmaceuticals | 55 | |
| Amy MBA | Terns Pharmaceuticals | 54 | |
| Frank BeduAddo | PDS Biotechnology Corp | 60 | |
| Malte MD | Hookipa Pharma | 63 | |
| Richard Adcock | Immunitybio | 56 | |
| Eric MBA | Seres Therapeutics | 49 | |
Management Performance
| Return On Equity | -0.23 | ||||
| Return On Asset | -0.0476 |
Ardelyx Leadership Team
Elected by the shareholders, the Ardelyx's board of directors comprises two types of representatives: Ardelyx inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ardelyx. The board's role is to monitor Ardelyx's management team and ensure that shareholders' interests are well served. Ardelyx's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ardelyx's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Elizabeth Esq, Chief Secretary | ||
| Susan Rodriguez, Chief Officer | ||
| Michael Raab, CEO and President and Director | ||
| Elizabeth Grammer, Vice President General Counsel | ||
| Joseph Reilly, Senior Officer | ||
| CPA MST, CFO Treasurer | ||
| Robert Felsch, Senior Officer | ||
| Caitlin Lowie, Vice Relations | ||
| David Rosenbaum, Sr. VP of Drug Devel. | ||
| Kimia Keshtbod, Mang Relations | ||
| Robert Blanks, Chief Officer | ||
| Mike Kelliher, Executive Strategy | ||
| Eric Foster, Chief Officer | ||
| Karen Harrigan, Director Devel | ||
| Charon Sr, Chief Officer | ||
| Dan Pavicich, Director Devel | ||
| MPH MD, Chief Officer |
Ardelyx Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Ardelyx a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.23 | ||||
| Return On Asset | -0.0476 | ||||
| Profit Margin | (0.12) % | ||||
| Operating Margin | 0.07 % | ||||
| Current Valuation | 1.18 B | ||||
| Shares Outstanding | 238.36 M | ||||
| Shares Owned By Insiders | 2.17 % | ||||
| Shares Owned By Institutions | 64.38 % | ||||
| Number Of Shares Shorted | 27.9 M | ||||
| Price To Earning | (2.11) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Ardelyx Stock Analysis
When running Ardelyx's price analysis, check to measure Ardelyx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ardelyx is operating at the current time. Most of Ardelyx's value examination focuses on studying past and present price action to predict the probability of Ardelyx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ardelyx's price. Additionally, you may evaluate how the addition of Ardelyx to your portfolios can decrease your overall portfolio volatility.